Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504

Mol Cancer, 2014, 15:30

PubMed: 24927996

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed:

Oncotarget, 2015, 51: S659-S660

PubMed:

Julius Maximilians Universit, 2014, Kumari G

PubMed:

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	NGfmWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMECwN\|A{KM7:TR?=	M2rNZnNCVkeHUh?=
IST-MEL1	M2XFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvuWndKSzVyPUCuNFAxPDB5IN88US=>	M1K2b3NCVkeHUh?=
NCI-SNU-1	M1vwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonOTWM2OD1yLkCwNlA4KM7:TR?=	Mom0V2FPT0WU
FADU	NHH0cWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfETG1KSzVyPUCuNFAzODlizszN	M4fSV3NCVkeHUh?=
C32	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUCyUWJyUUN3ME2wMlAxOzB2IN88US=>	M4LzZXNCVkeHUh?=
D-566MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXiSVNKSzVyPUCuNFA{QSEQvF2=	MXrTRW5ITVJ?
LXF-289	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jWc2lEPTB;MD6wNFQyQSEQvF2=	MoC2V2FPT0WU
HGC-27	NWKxdVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlm5TWM2OD1yLkCwOVEh\|ryP	MlXMV2FPT0WU
RPMI-7951	M1PIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEC3NVch\|ryP	NEn1cotUSU6JRWK=
HSC-3	NXLNc3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX3WYhKSzVyPUCuNFA6OjlizszN	MnOzV2FPT0WU
MIA-PaCa-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvZ[YYxUUN3ME2wMlAyODB7IN88US=>	MlLWV2FPT0WU
KS-1	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEGzOVUh\|ryP	NUHLW3IyW0GQR1XS
CAL-51	NFXS[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwMEG0NFUh\|ryP	MV\TRW5ITVJ?
MDA-MB-361	M{fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULVNFl2UUN3ME2wMlAyPDl3IN88US=>	NIridWFUSU6JRWK=
TI-73	M{C3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTrTWM2OD1yLkCxO\|k3KM7:TR?=	M1HNZ3NCVkeHUh?=
AGS	NUW5cXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zkZWlEPTB;MD6wNVk{QCEQvF2=	NIHifXZUSU6JRWK=
NCI-H460	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTYVIdxUUN3ME2wMlAyQTd2IN88US=>	M1z5d3NCVkeHUh?=
A204	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjrSYd{UUN3ME2wMlAzOjR7IN88US=>	NFfFXYRUSU6JRWK=
CHL-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm1TWM2OD1yLkCyNlUyKM7:TR?=	M2nQO3NCVkeHUh?=
DU-4475	NHf4VopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LOSmlEPTB;MD6wNlI3OSEQvF2=	NVjP[llEW0GQR1XS
CGTH-W-1	NX:yNFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jYSGlEPTB;MD6wNlM1QSEQvF2=	MXXTRW5ITVJ?
HCC2218	M4Xj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\FeVNRUUN3ME2wMlAzPDl2IN88US=>	MWnTRW5ITVJ?
A2780	NYPuWW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMEK1N\|Eh\|ryP	M{jYfXNCVkeHUh?=
NCI-H720	NFPoTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvTb3BRUUN3ME2wMlAzPTR4IN88US=>	M2jB[3NCVkeHUh?=
NCI-N87	NFHkVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\oTWM2OD1yLkCyOVk{KM7:TR?=	M1\kb3NCVkeHUh?=
CHP-212	NIi4RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrIUGdKSzVyPUCuNFI3OjhizszN	MXvTRW5ITVJ?
NCI-H23	MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoGzTWM2OD1yLkCyOlY2KM7:TR?=	NWi1PJBbW0GQR1XS
D-263MG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEK3PFYh\|ryP	M3vqfXNCVkeHUh?=
ME-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7GcmFKSzVyPUCuNFI5QTFizszN	NEHNRlBUSU6JRWK=
SW982	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LHTWlEPTB;MD6wNlk6QSEQvF2=	MXfTRW5ITVJ?
OE19	M1PBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLqfGJbUUN3ME2wMlA{ODd5IN88US=>	NX7VVpU6W0GQR1XS
SK-LU-1	M3S0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\5SWlEPTB;MD6wN\|A5OiEQvF2=	MULTRW5ITVJ?
H4	NX7TR4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvJdnJKSzVyPUCuNFMxQSEQvF2=	M4jWdnNCVkeHUh?=
HT-144	NX3LZVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzhTpN2UUN3ME2wMlA{ODl\|IN88US=>	NH60NGVUSU6JRWK=
SK-UT-1	NV7NUIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITn[29KSzVyPUCuNFMyPzhizszN	MWrTRW5ITVJ?
D-336MG	NXy5RVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEOzNFkh\|ryP	MVLTRW5ITVJ?
MDA-MB-175-VII	NWW3NnFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1z1emlEPTB;MD6wN\|M2PCEQvF2=	NFX0TYpUSU6JRWK=
GAMG	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNS5NKSzVyPUCuNFM1OzVizszN	NGrCZm9USU6JRWK=
CP50-MEL-B	NWfMXWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1O1S2lEPTB;MD6wN\|Q2KM7:TR?=	MmjmV2FPT0WU
OVCAR-5	NYrv[mNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfHcFBoUUN3ME2wMlA{PDhizszN	MWrTRW5ITVJ?
SK-MES-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHGTWM2OD1yLkCzOlA3KM7:TR?=	MVPTRW5ITVJ?
VM-CUB-1	M135b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfXTWRKSzVyPUCuNFM3PTdizszN	NYPSdmFTW0GQR1XS
WM-115	NWXO[GZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TNPGlEPTB;MD6wN\|c3OiEQvF2=	Ml3rV2FPT0WU
DSH1	M4j3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEO4NFch\|ryP	MlK1V2FPT0WU
Becker	NEOwTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jZVmlEPTB;MD6wN\|g5PSEQvF2=	Ml;1V2FPT0WU
SW962	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nZfGlEPTB;MD6wN\|k1PSEQvF2=	MWTTRW5ITVJ?
TYK-nu	NWLj[pN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrObVJKSzVyPUCuNFM6QDVizszN	Mo\FV2FPT0WU
HO-1-N-1	NYHYbohMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIexZ\|JKSzVyPUCuNFQxOjFizszN	NI\DU4lUSU6JRWK=
T98G	M1PHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMESxNFMh\|ryP	M2\VOXNCVkeHUh?=
ACN	NVPj[ZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzVcFlrUUN3ME2wMlA1OTZ{IN88US=>	NXnEOIVbW0GQR1XS
SW780	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDidVlKSzVyPUCuNFQzODNizszN	M3\RcnNCVkeHUh?=
Detroit562	NF7IVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S3eGlEPTB;MD6wOFI{QSEQvF2=	NX:yOG0{W0GQR1XS
BB49-HNC	MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[3NWlEPTB;MD6wOFI1OyEQvF2=	MonBV2FPT0WU
HN	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\QcGlEPTB;MD6wOFI4OiEQvF2=	NHXXOXNUSU6JRWK=
H9	NGHSdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMESzO\|Eh\|ryP	M2fvVnNCVkeHUh?=
VA-ES-BJ	M4PMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnCbmhGUUN3ME2wMlA1PDR5IN88US=>	MVHTRW5ITVJ?
MEL-JUSO	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Pmb2lEPTB;MD6wOFQ4PSEQvF2=	MXLTRW5ITVJ?
BT-474	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7WUFZKUUN3ME2wMlA1PSEQvF2=	NYm1XVJDW0GQR1XS
CaR-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPzTWM2OD1yLkC0OVQ6KM7:TR?=	NHPw[4NUSU6JRWK=
PSN1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMES2NFMh\|ryP	NFLocI1USU6JRWK=
KYSE-510	M4P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL4TWM2OD1yLkC0OlQ6KM7:TR?=	NX;DT3NEW0GQR1XS
KP-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XmTmlEPTB;MD6wOFc2OyEQvF2=	NXnWSHRHW0GQR1XS
KYSE-410	M16yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMES3O\|Ih\|ryP	NVHSSWpHW0GQR1XS
G-402	NWTpRVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe2cGpkUUN3ME2wMlA1Pzh7IN88US=>	MYjTRW5ITVJ?
DOK	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMES5NFIh\|ryP	NV[3fHFNW0GQR1XS
COR-L88	NFvXVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMES5NVIh\|ryP	NHrlPXRUSU6JRWK=
SKG-IIIa	M1fiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC4TWM2OD1yLkC0PVg3KM7:TR?=	MVnTRW5ITVJ?
AN3-CA	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jER2lEPTB;MD6wOUDPxE1?	NUPZc3pJW0GQR1XS
SW48	M2\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fNVGlEPTB;MD6wOVA{QSEQvF2=	M{XiO3NCVkeHUh?=
YKG-1	NEDKTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3NNHA5UUN3ME2wMlA2ODdzIN88US=>	NWHWZ\|VLW0GQR1XS
KYSE-150	M1KxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXmeG1zUUN3ME2wMlA2OjN3IN88US=>	M1\5RnNCVkeHUh?=
HuO-3N1	NWf0OYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXZbW1jUUN3ME2wMlA2OjN5IN88US=>	MlXEV2FPT0WU
LB1047-RCC	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrJTWM2OD1yLkC1Nlk3KM7:TR?=	NUnURZJvW0GQR1XS
NCI-H2030	NGr6eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2X0RWlEPTB;MD6wOVQyPCEQvF2=	MXXTRW5ITVJ?
YH-13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMEW3NlIh\|ryP	MkXHV2FPT0WU
5637	NVLhTVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPoTWM2OD1yLkC1O\|Qh\|ryP	Ml6yV2FPT0WU
LOXIMVI	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMEW4O\|Ih\|ryP	NIHoVFlUSU6JRWK=
GT3TKB	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTqemVsUUN3ME2wMlA2QTR{IN88US=>	NVrTNFRPW0GQR1XS
TCCSUP	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH32b2tKSzVyPUCuNFU6PjRizszN	MU\TRW5ITVJ?
EPLC-272H	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLzTWM2OD1yLkC2NlA2KM7:TR?=	M1\3b3NCVkeHUh?=
LU-99A	NYDS[mJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTKTWM2OD1yLkC2NlM4KM7:TR?=	NGfDTZlUSU6JRWK=
NCI-H1755	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXlb3RjUUN3ME2wMlA3OzRzIN88US=>	Mo\xV2FPT0WU
KM12	NI\rNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\Q[45KSzVyPUCuNFY{PDhizszN	MUfTRW5ITVJ?
SF295	NYnWPJNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPVbFJCUUN3ME2wMlA3PDV{IN88US=>	NGPJfItUSU6JRWK=
MZ2-MEL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofFTWM2OD1yLkC2OVU{KM7:TR?=	NY\qOVA{W0GQR1XS
HEC-1	NUKxWHpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nXVGlEPTB;MD6wOlU5QCEQvF2=	MVHTRW5ITVJ?
SW684	NH;qSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnpeHlSUUN3ME2wMlA3PTlzIN88US=>	MV3TRW5ITVJ?
SF539	NIK0dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTuOodGUUN3ME2wMlA3PjhzIN88US=>	MXXTRW5ITVJ?
GMS-10	NYnBWmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL6WoVKSzVyPUCuNFY3QTlizszN	NWD6T\|dnW0GQR1XS
MV-4-11	M13P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnzRYRwUUN3ME2wMlA3QDB\|IN88US=>	NHOz[2dUSU6JRWK=
HT-29	M37qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnVS3dYUUN3ME2wMlA3QTF7IN88US=>	NFzqVYNUSU6JRWK=
23132-87	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XRe2lEPTB;MD6wOlk2KM7:TR?=	NES0dYNUSU6JRWK=
SW620	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17rXGlEPTB;MD6wO\|AzPiEQvF2=	NXPUfWZKW0GQR1XS
HCC1806	M{j4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMEexN\|Eh\|ryP	MmH4V2FPT0WU
Hs-578-T	NXe0WnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjIbJBUUUN3ME2wMlA4OjB6IN88US=>	MlzpV2FPT0WU
A2058	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[0U3pKSzVyPUCuNFczOjhizszN	NX\IeWJYW0GQR1XS
MEL-HO	M1jyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXkRlhKSzVyPUCuNFczPTVizszN	M3TtZnNCVkeHUh?=
HCC2998	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTkUG9KSzVyPUCuNFc{PDdizszN	NGrrO29USU6JRWK=
HuO9	M3exW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEe1PFkh\|ryP	Ml\tV2FPT0WU
CAL-39	NV[3[JY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r2eWlEPTB;MD6wO\|c3PiEQvF2=	NIfoOmZUSU6JRWK=
M14	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqzVJZuUUN3ME2wMlA4QTF\|IN88US=>	NHrJVoxUSU6JRWK=
BFTC-909	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvYSpdWUUN3ME2wMlA4QTZ7IN88US=>	Mmm4V2FPT0WU
TE-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlniTWM2OD1yLkC3PVk3KM7:TR?=	NFLlb4pUSU6JRWK=
TGBC1TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEiwOFMh\|ryP	NF;CeGpUSU6JRWK=
L-363	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fEN2lEPTB;MD6wPFIxPiEQvF2=	M2LkbXNCVkeHUh?=
A431	NYXBfYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zFdGlEPTB;MD6wPFIyKM7:TR?=	M3zidnNCVkeHUh?=
MKN45	NH\NS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LocWlEPTB;MD6wPFIyQSEQvF2=	M3jH[3NCVkeHUh?=
HT-1080	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\GZ5VtUUN3ME2wMlA5PDN7IN88US=>	NFrndnRUSU6JRWK=
OVCAR-8	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HkfWlEPTB;MD6wPFYzOiEQvF2=	MkXCV2FPT0WU
LCLC-97TM1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M134Z2lEPTB;MD6wPFczQCEQvF2=	NVXYNGNOW0GQR1XS
M059J	MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml71TWM2OD1yLkC5NFI4KM7:TR?=	NFTScYpUSU6JRWK=
SK-MEL-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr1TGhCUUN3ME2wMlA6ODZizszN	NXz4Wm1EW0GQR1XS
TE-1	NVzYTJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\NN2lEPTB;MD6wPVIxPCEQvF2=	NICzOoJUSU6JRWK=
KYSE-180	NUHWZ49LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwMEmyOlIh\|ryP	NFHIR4ZUSU6JRWK=
D-247MG	NH3MV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:1OWlEPTB;MD6wPVQ2PSEQvF2=	MXvTRW5ITVJ?
8-MG-BA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW5SZBkUUN3ME2wMlA6PDd{IN88US=>	NGD0NG1USU6JRWK=
NCI-H1792	NGjzbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmH2TWM2OD1yLkC5OlE5KM7:TR?=	MoHuV2FPT0WU
MCF7	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTJWFFpUUN3ME2wMlA6Pjd5IN88US=>	MU\TRW5ITVJ?
NCI-H2122	NEjYOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7ZdWlIUUN3ME2wMlA6PzR3IN88US=>	MnXLV2FPT0WU
EFO-27	NHPCRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITlcYxKSzVyPUCuNFk6QTdizszN	NVOxZWpXW0GQR1XS
LB2241-RCC	M3T2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmG1TWM2OD1yLkGwNFU1KM7:TR?=	M3TTNnNCVkeHUh?=
SN12C	NG\XcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInoSGhKSzVyPUCuNVAyODdizszN	M1HK[HNCVkeHUh?=
A498	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjQTWM2OD1yLkGwNVgh\|ryP	MX7TRW5ITVJ?
PANC-03-27	NHvvZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fOeGlEPTB;MD6xNFI5PiEQvF2=	MnK3V2FPT0WU
NCI-H1581	NX:0OXBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfBXmgzUUN3ME2wMlExOjlizszN	NHHHT2tUSU6JRWK=
U-87-MG	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXTdJlKSzVyPUCuNVA{ODdizszN	MX;TRW5ITVJ?
G-401	M3Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\PXpA3UUN3ME2wMlExOzV\|IN88US=>	M1HYU3NCVkeHUh?=
SiHa	NX7yfXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\TXoN{UUN3ME2wMlExPDh4IN88US=>	NV;weGZFW0GQR1XS
U251	NVjNXnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTV[XhVUUN3ME2wMlExPTJ3IN88US=>	NHn0eHhUSU6JRWK=
MMAC-SF	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqwTnFRUUN3ME2wMlExPTNzIN88US=>	NX:4OFJZW0GQR1XS
BB65-RCC	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;oWnVkUUN3ME2wMlExPTV2IN88US=>	M1jFRXNCVkeHUh?=
NKM-1	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMUC2OlYh\|ryP	NFLhdpBUSU6JRWK=
HD-MY-Z	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMUC4O\|Mh\|ryP	MULTRW5ITVJ?
TGBC11TKB	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LmPGlEPTB;MD6xNFkxOyEQvF2=	NGX4WmdUSU6JRWK=
COLO-679	NETOVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PYUGlEPTB;MD6xNVIyOSEQvF2=	MlnOV2FPT0WU
TE-8	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\Tb3BKSzVyPUCuNVEzPjRizszN	M{[0O3NCVkeHUh?=
SK-MEL-28	NFXLZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vjZ2lEPTB;MD6xNVMzOSEQvF2=	MlWyV2FPT0WU
SH-4	NV\oVJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMUGzOVYh\|ryP	NVHk[FI4W0GQR1XS
KALS-1	NVrsVZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;0TWM2OD1yLkGxN\|k{KM7:TR?=	M1GzXHNCVkeHUh?=
RKO	NXzwPVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe2[WFUUUN3ME2wMlEyPzZ2IN88US=>	MkPZV2FPT0WU
OMC-1	NGPu[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjaTWM2OD1yLkGxO\|k4KM7:TR?=	M4HWSHNCVkeHUh?=
BT-549	NHO0V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13nOGlEPTB;MD6xNVc6QSEQvF2=	MojNV2FPT0WU
NCI-H28	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUG4NVch\|ryP	NUn5d3FWW0GQR1XS
RXF393	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHRZnJKSzVyPUCuNVE6QDJizszN	MlPvV2FPT0WU
COLO-829	M17JUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHQTWM2OD1yLkGyNFA2KM7:TR?=	M3HzfHNCVkeHUh?=
HMV-II	NELDU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFuwbVFKSzVyPUCuNVIxOiEQvF2=	M4\kPHNCVkeHUh?=
SW1990	NX[0VFRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMUKxOVch\|ryP	NXXyN\|ZrW0GQR1XS
NCI-H1437	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLZTWM2OD1yLkGyNVU4KM7:TR?=	NXrlRZFYW0GQR1XS
SNB75	NGCyUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMUKxOlkh\|ryP	MoHDV2FPT0WU
EW-3	NET6O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMUK2OlEh\|ryP	M4T1RXNCVkeHUh?=
SAS	M1:5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUK2PUDPxE1?	MULTRW5ITVJ?
NCI-H1666	NGe2OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fyfWlEPTB;MD6xNlc4PCEQvF2=	NED4WVNUSU6JRWK=
A375	M3\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mwWWlEPTB;MD6xNlc4QCEQvF2=	Mk\zV2FPT0WU
CAMA-1	Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTUTWM2OD1yLkGyPVI1KM7:TR?=	MmDHV2FPT0WU
HuP-T4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW1U4JKSzVyPUCuNVI6PDNizszN	NVvoe3V[W0GQR1XS
NCI-H292	NXXQNGV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\qTWM2OD1yLkGzNVEh\|ryP	MYHTRW5ITVJ?
PC-14	NX\iOYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMUOyNVEh\|ryP	MmO3V2FPT0WU
BPH-1	NIfz[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfifZZKUUN3ME2wMlE{PDFizszN	MoTGV2FPT0WU
GAK	NWXRfmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HZUGlEPTB;MD6xN\|U3PyEQvF2=	MV;TRW5ITVJ?
VMRC-RCZ	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFexdmNKSzVyPUCuNVM4PjJizszN	NXfGWXZNW0GQR1XS
SK-MEL-24	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M322PGlEPTB;MD6xN\|g4KM7:TR?=	MkTEV2FPT0WU
LB831-BLC	NXT6[41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMUO4PFMh\|ryP	NFf6UHJUSU6JRWK=
NCI-H2452	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT0TWM2OD1yLkGzPVU3KM7:TR?=	MYjTRW5ITVJ?
RT-112	NXH0RodMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDnUJRKSzVyPUCuNVQxOzVizszN	NYO4WWZmW0GQR1XS
GP5d	M3\OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;NZmU6UUN3ME2wMlE1OTB2IN88US=>	NUj3VIZ7W0GQR1XS
LC-2-ad	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHLVWhKSzVyPUCuNVQyOjFizszN	MojsV2FPT0WU
MPP-89	M33Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPs[JU5UUN3ME2wMlE1OTJ3IN88US=>	MXTTRW5ITVJ?
NUGC-3	NFyzOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPVTWM2OD1yLkG0OFc5KM7:TR?=	M2\rVnNCVkeHUh?=
GI-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPaTWM2OD1yLkG0OVU5KM7:TR?=	NXnmVItZW0GQR1XS
HCC1419	M3\afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnLTWM2OD1yLkG0OVc3KM7:TR?=	MVfTRW5ITVJ?
SW1573	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzzVmo1UUN3ME2wMlE1PzV6IN88US=>	M2T3NXNCVkeHUh?=
NCI-H2347	NUD0VINVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TkcWlEPTB;MD6xOFg{QSEQvF2=	M{\lR3NCVkeHUh?=
Mewo	NHnG[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO0TWM2OD1yLkG0PFg6KM7:TR?=	NF34VIFUSU6JRWK=
639-V	MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUWwNVMh\|ryP	MVrTRW5ITVJ?
AsPC-1	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLye\|BSUUN3ME2wMlE2OjJ3IN88US=>	Ml3tV2FPT0WU
NCI-H1648	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nEXmlEPTB;MD6xOVI{OiEQvF2=	Mo\uV2FPT0WU
786-0	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrwclFKSzVyPUCuNVU{QDFizszN	MV;TRW5ITVJ?
ETK-1	NEWzOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnwXmdKSzVyPUCuNVU6KM7:TR?=	MVTTRW5ITVJ?
BxPC-3	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTzTWM2OD1yLkG1PVY3KM7:TR?=	MljkV2FPT0WU
CAL-62	NWLVe5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv1ZpVKSzVyPUCuNVYyPjlizszN	M4nofXNCVkeHUh?=
HCC1937	NFXaW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvBTWM2OD1yLkG2Nlc2KM7:TR?=	NEHXNZJUSU6JRWK=
NCI-H1299	NV7VO3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWG1RXZGUUN3ME2wMlE3Ojh3IN88US=>	M{LMVHNCVkeHUh?=
SW1088	NHSxWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHsTWM2OD1yLkG2OFE{KM7:TR?=	MVPTRW5ITVJ?
FTC-133	M1fGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T5WWlEPTB;MD6xOlU1KM7:TR?=	Ml:wV2FPT0WU
OC-314	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7BXXdUUUN3ME2wMlE3PjlizszN	MorvV2FPT0WU
SCC-9	NXrsNVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzyXGRRUUN3ME2wMlE3PzF4IN88US=>	NFjySGVUSU6JRWK=
HT-1376	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz1R2ZKSzVyPUCuNVY6OzZizszN	MXnTRW5ITVJ?
U-2-OS	NInCVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUP1VHdsUUN3ME2wMlE4OTd\|IN88US=>	NEfIb5dUSU6JRWK=
COLO-824	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUeyPVQh\|ryP	MUfTRW5ITVJ?
BB30-HNC	NY\iV4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPGTWM2OD1yLkG3N\|Mh\|ryP	Ml;LV2FPT0WU
NCI-H2087	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn4cGRSUUN3ME2wMlE4OzZ6IN88US=>	MkLJV2FPT0WU
NCI-H2170	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3vTWM2OD1yLkG3OVM3KM7:TR?=	NGm3O3hUSU6JRWK=
SK-OV-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXm[G5XUUN3ME2wMlE4PTdzIN88US=>	NVXndIR2W0GQR1XS
MZ7-mel	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrPUnZKSzVyPUCuNVc3PDlizszN	NXP6UYF{W0GQR1XS
NCI-H650	NHfjVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTlTWM2OD1yLkG3OlgzKM7:TR?=	NH\FZXBUSU6JRWK=
KOSC-2	NYnwfVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLhTWM2OD1yLkG3O\|M1KM7:TR?=	M{XsPHNCVkeHUh?=
SCC-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTPZldKSzVyPUCuNVc4PzdizszN	MmHvV2FPT0WU
MDA-MB-157	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD2N5lPUUN3ME2wMlE5ODh{IN88US=>	NH:wdopUSU6JRWK=
KYSE-520	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13uSWlEPTB;MD6xPFIh\|ryP	MV\TRW5ITVJ?
LK-2	NWX2fJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLSTmtnUUN3ME2wMlE5OzB\|IN88US=>	M1\nWnNCVkeHUh?=
KNS-81-FD	NFTtWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMUizPVQh\|ryP	NXXNclhJW0GQR1XS
IGROV-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;CTWM2OD1yLkG4OFQ{KM7:TR?=	NXrvcFV7W0GQR1XS
DEL	M17JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPaTWM2OD1yLkG4OFUh\|ryP	MnL6V2FPT0WU
NCI-H1395	NFPBclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf0XmFKSzVyPUCuNVg3QDJizszN	NXX2[ZhlW0GQR1XS
JEG-3	NFnR[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHFUpVVUUN3ME2wMlE5PzB3IN88US=>	MWTTRW5ITVJ?
BCPAP	M1LJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELMcmZKSzVyPUCuNVg5PzJizszN	MUjTRW5ITVJ?
CAL-27	M1TpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjkOHlKSzVyPUCuNVkxOjJizszN	MYjTRW5ITVJ?
RD	NVnrXJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvOeWZFUUN3ME2wMlE6OTF\|IN88US=>	NYjmUFdpW0GQR1XS
RVH-421	M2LOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\CXYtvUUN3ME2wMlE6OTF4IN88US=>	MoG3V2FPT0WU
Capan-2	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TTdGlEPTB;MD6xPVI2PiEQvF2=	NY[2eFBjW0GQR1XS
COLO-680N	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPZTWM2OD1yLkG5N\|Y1KM7:TR?=	NXnlU\|ZPW0GQR1XS
NCI-H1650	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLNTWM2OD1yLkKwNFU4KM7:TR?=	M{[5eHNCVkeHUh?=
SBC-5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUC5ZYlMUUN3ME2wMlIxOTF6IN88US=>	NITsU2tUSU6JRWK=
U031	NHnqTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMkC1OFch\|ryP	MXHTRW5ITVJ?
S-117	NWP1c4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPpTWM2OD1yLkKwOVY1KM7:TR?=	NFvleWRUSU6JRWK=
DoTc2-4510	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLYO5lXUUN3ME2wMlIxPzZ7IN88US=>	NWfINGpbW0GQR1XS
AM-38	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnmTWM2OD1yLkKwPFQ5KM7:TR?=	M3f2R3NCVkeHUh?=
A172	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLXPI9KSzVyPUCuNlExOjJizszN	MkH5V2FPT0WU
HPAF-II	NGXESmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7PN5RKSzVyPUCuNlEzPjRizszN	MW\TRW5ITVJ?
769-P	NH3zSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnTUFgxUUN3ME2wMlIyOjhizszN	MYnTRW5ITVJ?
MFE-280	NV3Cemh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPITG5sUUN3ME2wMlIyOjl6IN88US=>	MVvTRW5ITVJ?
TE-9	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[zTWM2OD1yLkKxO\|g3KM7:TR?=	NVTFZ5J6W0GQR1XS
C2BBe1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;BS\|hRUUN3ME2wMlIzOTlizszN	NFXzWVhUSU6JRWK=
EoL-1-cell	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fGTWlEPTB;MD6yNlIxOyEQvF2=	NX\ESXRoW0GQR1XS
G-361	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnFUmNKSzVyPUCuNlI3QDJizszN	NXPrfVlVW0GQR1XS
KYSE-270	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqxU\|RKSzVyPUCuNlMxQDRizszN	NHnaUVdUSU6JRWK=
TK10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHy5PJRKSzVyPUCuNlMyOTdizszN	MYHTRW5ITVJ?
ML-2	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XDcWlEPTB;MD6yN\|EyQSEQvF2=	MkG1V2FPT0WU
MHH-ES-1	M3rtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMkO2PFEh\|ryP	M3jqXHNCVkeHUh?=
BHY	M3TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETjWFlKSzVyPUCuNlM3QTFizszN	NH:4WIFUSU6JRWK=
LS-513	NX;mfVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLt[YlKSzVyPUCuNlM6PjFizszN	MX3TRW5ITVJ?
COLO-678	M4SyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXQXYVkUUN3ME2wMlI1ODR2IN88US=>	NFnSNm5USU6JRWK=
NCI-H747	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMkSxOlkh\|ryP	NUHTeZZUW0GQR1XS
K5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXEO2FKSzVyPUCuNlQ{QCEQvF2=	NWnHeoJZW0GQR1XS
OS-RC-2	NG[4fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfvXVRnUUN3ME2wMlI1PTB7IN88US=>	NUXDUWJCW0GQR1XS
KINGS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVu0SmJpUUN3ME2wMlI1PTJ7IN88US=>	MXzTRW5ITVJ?
SCC-25	NVTLZXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXrTWM2OD1yLkK0OVY{KM7:TR?=	M{ftRnNCVkeHUh?=
CAPAN-1	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMkS3PFMh\|ryP	MlHGV2FPT0WU
ESS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3WwV2lEPTB;MD6yOFgxPSEQvF2=	M2DnXnNCVkeHUh?=
TE-6	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL3TWM2OD1yLkK1O\|Uh\|ryP	MU\TRW5ITVJ?
LB2518-MEL	M3HEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfTdXZKUUN3ME2wMlI2Pzd5IN88US=>	MXPTRW5ITVJ?
COLO-800	M2CzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMkW4NVIh\|ryP	NGq3SlBUSU6JRWK=
LU-134-A	NHj1do9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHSTWM2OD1yLkK2NVM3KM7:TR?=	MmC1V2FPT0WU
NCI-H1155	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMk[xOlIh\|ryP	MXXTRW5ITVJ?
MFM-223	NVzSOXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMk[zOlMh\|ryP	NVn5dIpIW0GQR1XS
HTC-C3	MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD4TWM2OD1yLkK2OVA3KM7:TR?=	MnvFV2FPT0WU
HCT-116	NWXmOVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO5[pExUUN3ME2wMlI3PTl7IN88US=>	M1XM[HNCVkeHUh?=
Ca-Ski	NXLPdXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMk[2O\|gh\|ryP	MYjTRW5ITVJ?
SBC-1	M4rWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\FWGlEPTB;MD6yOlc1OiEQvF2=	NI\HNoNUSU6JRWK=
NB69	M4fPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMkewPFch\|ryP	NEPRT\|NUSU6JRWK=
J82	NVfJTmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH4XFlKSzVyPUCuNlczPjVizszN	M33sUHNCVkeHUh?=
U-118-MG	NWTtfHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjiNG05UUN3ME2wMlI4PTd7IN88US=>	NWLxWZVVW0GQR1XS
NCI-H1355	M1T3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH5TlVKSzVyPUCuNlgxPzRizszN	MV7TRW5ITVJ?
NCI-H1048	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD0dlJ7UUN3ME2wMlI5QTV4IN88US=>	NYniRo46W0GQR1XS
SW954	NGD2fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMkmyNlch\|ryP	MVLTRW5ITVJ?
NMC-G1	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMkmyO\|ch\|ryP	NGW5dmFUSU6JRWK=
SW1710	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMkm0PVQh\|ryP	MU\TRW5ITVJ?
KY821	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXGTW1vUUN3ME2wMlI6QDd{IN88US=>	M{nhfXNCVkeHUh?=
HCC38	M3Pje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX6SnFKUUN3ME2wMlMxODd6IN88US=>	MX\TRW5ITVJ?
NCI-SNU-5	M4izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLSZoJKSzVyPUCuN\|A2PCEQvF2=	M4LFUnNCVkeHUh?=
ES8	M1XjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwM{C3PFQh\|ryP	M3\OcHNCVkeHUh?=
COLO-792	NWfsSo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jmOmlEPTB;MD6zNVI2OSEQvF2=	M3zQTHNCVkeHUh?=
BFTC-905	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwM{G1NlEh\|ryP	MUTTRW5ITVJ?
ChaGo-K-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGqwZXBKSzVyPUCuN\|E4OTVizszN	M2C0eHNCVkeHUh?=
Daoy	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmwTWM2OD1yLkOxO\|I{KM7:TR?=	MVTTRW5ITVJ?
SJSA-1	NHnHN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LoNWlEPTB;MD6zNVg1PyEQvF2=	MX\TRW5ITVJ?
KNS-62	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwM{KwPFgh\|ryP	NXn4VVZoW0GQR1XS
CAKI-1	M3;VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLhdYVMUUN3ME2wMlMzOTFzIN88US=>	M2XIV3NCVkeHUh?=
UACC-62	M1vrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHRTWM2OD1yLkOyNlI4KM7:TR?=	NGCxbldUSU6JRWK=
HuCCT1	NHvBWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX74SFhuUUN3ME2wMlMzOjh\|IN88US=>	MYnTRW5ITVJ?
CTB-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwM{K3OVMh\|ryP	MmG5V2FPT0WU
NTERA-S-cl-D1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPRTWM2OD1yLkOyPFM3KM7:TR?=	NWHxSphPW0GQR1XS
T-24	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\IWGlEPTB;MD6zN\|E2QSEQvF2=	NX\iUZFPW0GQR1XS
KYSE-70	NXPWeollT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwM{OyPFMh\|ryP	NH74b5JUSU6JRWK=
SW626	NUPE[lB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwM{O1N\|Ih\|ryP	M37pfnNCVkeHUh?=
LB996-RCC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mom2TWM2OD1yLkOzOlE6KM7:TR?=	MmTpV2FPT0WU
DMS-273	NWPEWpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHQeYJKSzVyPUCuN\|M6OTZizszN	M12wcHNCVkeHUh?=
SW1783	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzmTG96UUN3ME2wMlM{QTl5IN88US=>	MljvV2FPT0WU
KU812	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDBTWM2OD1yLkO0NFM5KM7:TR?=	NFnsSFZUSU6JRWK=
HSC-2	NEn5VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTKTZprUUN3ME2wMlM1ODV\|IN88US=>	MXLTRW5ITVJ?
A3-KAW	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuwOot6UUN3ME2wMlM1OTZ{IN88US=>	NGHsUFZUSU6JRWK=
COLO-684	M4rsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwM{S1NFEh\|ryP	NV\xPHhPW0GQR1XS
NCI-H2405	NIL2PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\mcI5KSzVyPUCuN\|Q3OzFizszN	NWXXOFhUW0GQR1XS
NCI-H2228	MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzFTWM2OD1yLkO1N\|U4KM7:TR?=	NGPXNnpUSU6JRWK=
NB13	NV3sS29pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPSSnBZUUN3ME2wMlM3QDJ7IN88US=>	NX7TNoJjW0GQR1XS
no-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PiSmlEPTB;MD6zOlk2KM7:TR?=	M3PUSXNCVkeHUh?=
DK-MG	NGPrWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\kemlEPTB;MD6zO\|E5QCEQvF2=	NYr4S3V4W0GQR1XS
NBsusSR	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjsZmVyUUN3ME2wMlM4Ojh3IN88US=>	NH7IdVZUSU6JRWK=
KP-N-YS	NHj6U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjaZ4V{UUN3ME2wMlM4PDZ\|IN88US=>	M1;EVXNCVkeHUh?=
CFPAC-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXqNIpKSzVyPUCuN\|c2OThizszN	NHzwO\|lUSU6JRWK=
KARPAS-45	NWTqTXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDoWIVCUUN3ME2wMlM4QDZ{IN88US=>	NFvkZ2hUSU6JRWK=
NCI-H1793	NHTHeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwM{i1NUDPxE1?	NVTHRmh5W0GQR1XS
HCE-T	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rHRmlEPTB;MD6zPFYxOyEQvF2=	NVT5S\|dbW0GQR1XS
NCI-H520	NWHtRVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwM{i3NFMh\|ryP	NX73WlFuW0GQR1XS
HCC2157	M{PBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwM{i3PFEh\|ryP	NU\oZ3ByW0GQR1XS
EW-18	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzMU\|lKSzVyPUCuN\|g6PDFizszN	M4TtVnNCVkeHUh?=
RO82-W-1	NYjHdpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwM{m2PVkh\|ryP	MXHTRW5ITVJ?
HuP-T3	NHrNV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13QV2lEPTB;MD60NFE1OyEQvF2=	MoCwV2FPT0WU
PANC-10-05	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDTTWM2OD1yLkSxNVch\|ryP	NHHyTlBUSU6JRWK=
NCI-H1703	M3ztW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorqTWM2OD1yLkSxOFQ3KM7:TR?=	NFXUWoxUSU6JRWK=
TE-10	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjrVnltUUN3ME2wMlQyPDR5IN88US=>	NHXuRohUSU6JRWK=
HOS	M3XQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPkTXZKSzVyPUCuOFE3QDJizszN	NGPNUWhUSU6JRWK=
LN-405	NEXTVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv3[WZKSzVyPUCuOFE3QDdizszN	M{nhd3NCVkeHUh?=
A427	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfvTWM2OD1yLkSxPVgyKM7:TR?=	MlTYV2FPT0WU
CAL-12T	Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Sy[WlEPTB;MD60Nlc5KM7:TR?=	M1POVHNCVkeHUh?=
SW756	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfzR2VKSzVyPUCuOFQyQDNizszN	Ml[2V2FPT0WU
YAPC	M3foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHERlVRUUN3ME2wMlQ2ODhizszN	NIXPWZpUSU6JRWK=
GOTO	NFLhSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjSS5kzUUN3ME2wMlQ2OTZizszN	NXrlblV{W0GQR1XS
C3A	NIS3[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGmzZXZKSzVyPUCuOFU1OzdizszN	MYjTRW5ITVJ?
UM-UC-3	NGq0N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\idmlEPTB;MD60OVQ4KM7:TR?=	MUHTRW5ITVJ?
NCI-H1573	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlntTWM2OD1yLkS1OVY6KM7:TR?=	MU\TRW5ITVJ?
LS-411N	NE\DVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXuTWM2OD1yLkS2OVI4KM7:TR?=	M1HRS3NCVkeHUh?=
COR-L23	NHrld2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS4TWM2OD1yLkS2O\|Y1KM7:TR?=	NI\IU5dUSU6JRWK=
HCE-4	NXnqUIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwNEe0OFYh\|ryP	NX3p[48zW0GQR1XS
NCI-H2291	NVnMS2Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PpbWlEPTB;MD60O\|g6PiEQvF2=	MWXTRW5ITVJ?
A101D	NIrYTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEe3OIlKSzVyPUCuOFgxPTNizszN	MX;TRW5ITVJ?
HT-3	NWLrcnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm1TWM2OD1yLkS4NlE4KM7:TR?=	M2nFdXNCVkeHUh?=
HOP-62	NXXpXHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwNEm4OlUh\|ryP	Mo[5V2FPT0WU
PC-3	M3zwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXmV4ZKSzVyPUCuOVE2ODdizszN	NF7tXFZUSU6JRWK=
CTV-1	NVXpO5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLMTWM2OD1yLkWyOlY6KM7:TR?=	MkXrV2FPT0WU
PANC-08-13	M1T0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rLbmlEPTB;MD61N\|E4PyEQvF2=	M3e4VnNCVkeHUh?=
CAL-120	M1Kydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;oTWM2OD1yLkWzN\|k6KM7:TR?=	MnOxV2FPT0WU
UMC-11	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\mTWM2OD1yLkW1NlM1KM7:TR?=	MnrkV2FPT0WU
MSTO-211H	NGf1PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDxd5lKSzVyPUCuOVU4PjJizszN	NHO2Z4dUSU6JRWK=
NCI-H2126	NFv1ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjkd5RKSzVyPUCuOVY5OTVizszN	NFPTdlhUSU6JRWK=
SNU-C2B	NGnyRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPhbXBKSzVyPUCuOVc6PzdizszN	MoHhV2FPT0WU
DBTRG-05MG	NWTaUHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nSV2lEPTB;MD61PFA2OyEQvF2=	M4XaSXNCVkeHUh?=
MKN1	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwNUi3PFMh\|ryP	NIC2c5pUSU6JRWK=
ES3	M3rqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmryTWM2OD1yLkW5NVI1KM7:TR?=	Mnj6V2FPT0WU
OVCAR-3	NFLxR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGzO5R7UUN3ME2wMlU6OzRzIN88US=>	MWHTRW5ITVJ?
ACHN	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNkC1Olkh\|ryP	MXXTRW5ITVJ?
SW872	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNkC3OlMh\|ryP	M1;UOXNCVkeHUh?=
CP66-MEL	NI\acmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXwdJRKSzVyPUCuOlA6PjlizszN	NYXwfGd4W0GQR1XS
NCI-H661	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNkGxNFQh\|ryP	MlnOV2FPT0WU
UACC-893	NUjIb5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrGTWM2OD1yLk[zOlgyKM7:TR?=	MVPTRW5ITVJ?
JVM-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OycmlEPTB;MD62N\|gxPCEQvF2=	NUjXUYp3W0GQR1XS
SF268	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fDRmlEPTB;MD62OFM1QSEQvF2=	MXXTRW5ITVJ?
OCI-AML2	NY\DeGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz5TWM2OD1yLk[1N\|k4KM7:TR?=	M4nUXHNCVkeHUh?=
RPMI-8226	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXlTWM2OD1yLk[2N\|I{KM7:TR?=	NELyVmVUSU6JRWK=
MKN28	M1j4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHUe5U6UUN3ME2wMlY3PjJ2IN88US=>	NXjneJZ7W0GQR1XS
MDA-MB-453	NGTwOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTPWmZKSzVyPUCuOlcyQCEQvF2=	MWjTRW5ITVJ?
BV-173	NH;u[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Lk[2lEPTB;MD62PFY4QSEQvF2=	MUPTRW5ITVJ?
NCI-H358	M3fYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnnTWZOUUN3ME2wMlY5PzJ4IN88US=>	M1\ROnNCVkeHUh?=
NCI-H1651	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13YbWlEPTB;MD63JO69VQ>?	NVO1ZWxuW0GQR1XS
MDA-MB-415	NWTqWIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\DeGtKSzVyPUCuO\|A5OjlizszN	NYXiVGZrW0GQR1XS
8305C	NXmyXpNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwN{K0PVgh\|ryP	M3i4NnNCVkeHUh?=
EFM-19	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\HN4hrUUN3ME2wMlc{PjdzIN88US=>	MonsV2FPT0WU
RERF-LC-MS	M2D4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwN{S2NVMh\|ryP	M4OwW3NCVkeHUh?=
A388	MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrrTWM2OD1yLke2OFY4KM7:TR?=	M2TSUnNCVkeHUh?=
GI-ME-N	NWHIflVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n6dGlEPTB;MD63O\|I{PSEQvF2=	Mle5V2FPT0WU
IGR-1	NWTFXYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\BV3RKSzVyPUCuO\|kxPDNizszN	M33RSHNCVkeHUh?=
LNCaP-Clone-FGC	M4TGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjhUo5KSzVyPUCuPFAxODRizszN	NV:3bnM2W0GQR1XS
SK-MEL-3	NELo[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjXTWM2OD1yLkixOVA5KM7:TR?=	MlXIV2FPT0WU
UACC-257	M{HOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPmXXFuUUN3ME2wMlgzOjNzIN88US=>	MmjpV2FPT0WU
OE33	NVnTZYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\yTnhKSzVyPUCuPFUyODFizszN	NEnXUFFUSU6JRWK=
QIMR-WIL	NGfrcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DOWmlEPTB;MD64OVE1OSEQvF2=	NF;md3RUSU6JRWK=
NCI-H2009	M4Dk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;NTWM2OD1yLki1N\|EyKM7:TR?=	NUG1RpN7W0GQR1XS
NCI-H522	NWDIXmlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\wcW5KSzVyPUCuPFc4QDNizszN	MW\TRW5ITVJ?
Saos-2	NHjkPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTK[\|Z7UUN3ME2wMlg4QDdzIN88US=>	NXu2dnhyW0GQR1XS
NB17	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwOEiwNlUh\|ryP	NHW4S2FUSU6JRWK=
D-392MG	NWrpZm9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7FT5lKSzVyPUCuPFk{PTZizszN	M4XQWnNCVkeHUh?=
SHP-77	M1;PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkX6TWM2OD1yLkmwOFg2KM7:TR?=	NUDvSINOW0GQR1XS
SK-MEL-30	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrNTWM2OD1yLkmxNVg2KM7:TR?=	NFP0ZXJUSU6JRWK=
GCIY	M{fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\VTWM2OD1yLkmxPFQ{KM7:TR?=	MnPnV2FPT0WU
HCC70	NVTSR3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwOUKwOVkh\|ryP	NVi1U4txW0GQR1XS
LU-65	M4HBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS2TWM2OD1yLkmyOVkyKM7:TR?=	NWLpO5RZW0GQR1XS
NCI-H1563	NFy0SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuySZpKSzVyPUCuPVQ5PjVizszN	MYTTRW5ITVJ?
KURAMOCHI	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYe1R2F4UUN3ME2wMlk2OTl{IN88US=>	MWrTRW5ITVJ?
PA-1	M13JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;ROm1KSzVyPUCuPVU1OjRizszN	M3;DbHNCVkeHUh?=
NOS-1	NU\tPIRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fRXGlEPTB;MD65O\|Q5QSEQvF2=	MUfTRW5ITVJ?
NCI-H69	NI\yTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfqNldKSzVyPUCuPVc3OzRizszN	NXP0eGtZW0GQR1XS
KYSE-450	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXG5UZNiUUN3ME2wMlk5PjJ4IN88US=>	NWXsOZo{W0GQR1XS
8505C	NVjvWVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\WVHFKSzVyPUCuPVk6QDJizszN	MVrTRW5ITVJ?
TGBC24TKB	NUnVeYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXHfHhKSzVyPUGuNFAxQDRizszN	MkDrV2FPT0WU
PFSK-1	NVHpVlg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTFwMEG0Nlgh\|ryP	MnexV2FPT0WU
EKVX	NEXEV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DBT2lEPTB;MT6wN\|EzOSEQvF2=	NGDHbHpUSU6JRWK=
RCM-1	NInCXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjCTWM2OD1zLkC1OVA4KM7:TR?=	M1XPcnNCVkeHUh?=
SW900	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTFTWM2OD1zLkC3PFMh\|ryP	NYfYdZVwW0GQR1XS
D-542MG	M13BS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnWSJh2UUN3ME2xMlA4QDV3IN88US=>	NFrTVZdUSU6JRWK=
SK-PN-DW	M1HJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\u[mplUUN3ME2xMlExODV4IN88US=>	M4m1VHNCVkeHUh?=
NCI-H727	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn6SpV3UUN3ME2xMlExOTV2IN88US=>	MV3TRW5ITVJ?
SW837	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwMUC5OVQh\|ryP	M{nvOnNCVkeHUh?=
BT-20	NVT3O41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTFwMUGyNFQh\|ryP	NXXNfmxQW0GQR1XS
RH-18	NVuwXnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwMUOxNFMh\|ryP	MW\TRW5ITVJ?
TE-12	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrYe3JKSzVyPUGuNVM{OzNizszN	NXywPWw1W0GQR1XS
NB10	NWO4[Fd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTFwMUOzOFQh\|ryP	Moi1V2FPT0WU
AU565	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknpTWM2OD1zLkG1PVc{KM7:TR?=	NYLyXlJ3W0GQR1XS
OAW-42	NHvrdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PMTGlEPTB;MT6xPFMxPiEQvF2=	MlztV2FPT0WU
DJM-1	NWDMRWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXCOnRKSzVyPUGuNVk5QDFizszN	MlO3V2FPT0WU
HH	M3XvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHoc4oxUUN3ME2xMlI{QDNzIN88US=>	NETP[ndUSU6JRWK=
LAMA-84	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILsb5NKSzVyPUGuNlc{QTRizszN	MYfTRW5ITVJ?
KNS-42	NUXObY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwM{CyPVYh\|ryP	NV7oXY01W0GQR1XS
NCI-H2052	NXL4e4syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfGTWM2OD1zLkOwOVA4KM7:TR?=	M2\YSHNCVkeHUh?=
MLMA	NIPRdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrmeFNUUUN3ME2xMlMzPDB5IN88US=>	MoT0V2FPT0WU
NB12	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\JTWM2OD1zLkO1OlM3KM7:TR?=	NETnNmJUSU6JRWK=
NCI-H1838	NWjJdo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTTfpd6UUN3ME2xMlM3OzB4IN88US=>	NFvYco9USU6JRWK=
NCI-H526	NYTON3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjDR3NKSzVyPUGuN\|c5PTNizszN	NEH0R\|BUSU6JRWK=
LS-123	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXqTnF3UUN3ME2xMlM6ODl2IN88US=>	MoHhV2FPT0WU
HDLM-2	M2TDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fIVmlEPTB;MT6zPVI4OSEQvF2=	NHP6dodUSU6JRWK=
MC-IXC	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVWyU25LUUN3ME2xMlQzOzdzIN88US=>	MYnTRW5ITVJ?
HCT-15	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzNTWM2OD1zLkSzNFY5KM7:TR?=	NUjHVW9YW0GQR1XS
NCI-H596	NHSycnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2GzR2lEPTB;MT60OVA3OSEQvF2=	MVXTRW5ITVJ?
ZR-75-30	NV7JVJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjYTWM2OD1zLkS3NFgzKM7:TR?=	MonxV2FPT0WU
A704	NV[yWoFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTFwNk[1OlMh\|ryP	MVPTRW5ITVJ?
OVCAR-4	M3jrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnztTWM2OD1zLk[5OlA4KM7:TR?=	MmK0V2FPT0WU
SW1417	NHTVeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjqS4xwUUN3ME2xMlczQDR7IN88US=>	MXXTRW5ITVJ?
CAS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTFwN{O5N\|Yh\|ryP	MlLlV2FPT0WU
IST-SL1	M1zGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTIXI9KSzVyPUGuO\|k4PTlizszN	NIHNTpdUSU6JRWK=
A253	NIO3NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnX0TWM2OD1zLkiyNlM6KM7:TR?=	NFfFc2RUSU6JRWK=
EW-16	NV\WdY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTFwOEK4O\|Uh\|ryP	MljoV2FPT0WU
SK-NEP-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwOE[5PFgh\|ryP	MXrTRW5ITVJ?
NCI-H226	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzaTWM2OD1zLki5N\|U6KM7:TR?=	NU\OR\|QyW0GQR1XS
HOP-92	NETpbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[0TWM2OD1zLkm2NFk6KM7:TR?=	NGiwVJNUSU6JRWK=
NCI-H441	NH3ne25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTq[IIxUUN3ME2yMlAzOzN5IN88US=>	NEL3WVNUSU6JRWK=
LU-139	M3rFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJwMEOxNVQh\|ryP	NFnBVZhUSU6JRWK=
SJRH30	M37XRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVL4UHMxUUN3ME2yMlA1OjV\|IN88US=>	MVjTRW5ITVJ?
MG-63	NGflUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\nXoY3UUN3ME2yMlE1OTFzIN88US=>	MUjTRW5ITVJ?
NH-12	NHP6U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJwMUWwNFYh\|ryP	M1fFSnNCVkeHUh?=
NB7	NGn4RWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJwMUm2O\|Mh\|ryP	NYfpNJhvW0GQR1XS
LB771-HNC	M1TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;OTWM2OD1{LkKwOVk2KM7:TR?=	MVjTRW5ITVJ?
HCC1569	NFrXclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn6W4FKSzVyPUKuNlQ2QDNizszN	MUXTRW5ITVJ?
D-283MED	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X0ZWlEPTB;Mj6yOFc5OiEQvF2=	MknEV2FPT0WU
J-RT3-T3-5	M3Sxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjFTHVYUUN3ME2yMlI2OzVzIN88US=>	M2\rNnNCVkeHUh?=
ATN-1	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\4N2pEUUN3ME2yMlM{ODh{IN88US=>	MnLFV2FPT0WU
HCC1954	M1jXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJwM{S0NFgh\|ryP	MXjTRW5ITVJ?
SCC-15	M3rq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDTTWM2OD1{LkO5N\|EzKM7:TR?=	NEXqRYVUSU6JRWK=
COLO-668	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfFPYxKSzVyPUKuOFMzKM7:TR?=	M1PJcXNCVkeHUh?=
LB373-MEL-D	NG[3XnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorQTWM2OD1{LkW0Olc4KM7:TR?=	MWDTRW5ITVJ?
no-10	NYP5TlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XIZ2lEPTB;Mj61OFk1PyEQvF2=	NF76dHRUSU6JRWK=
HT-1197	M2rYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTJwNkOxPFgh\|ryP	M173WnNCVkeHUh?=
DU-145	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYixOWpOUUN3ME2yMlc6OTZ{IN88US=>	NF7mcmdUSU6JRWK=
SK-N-AS	M{jhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHXbHlKSzVyPUKuPFQ3QTJizszN	MXvTRW5ITVJ?
MOLT-4	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrBOldKSzVyPUKuPFU{OjJizszN	M4q0dnNCVkeHUh?=
EW-22	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXGTWM2OD1{LkmyPFQyKM7:TR?=	M{HXUHNCVkeHUh?=
DB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\E[5VDUUN3ME2yMlk4PzV7IN88US=>	MX7TRW5ITVJ?
HL-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP0TYJKSzVyPUOuNFQ{PzZizszN	M2H6[3NCVkeHUh?=
SK-N-DZ	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmO3TWM2OD1\|LkC1NFc2KM7:TR?=	M4n3RXNCVkeHUh?=
NY	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\jNlBqUUN3ME2zMlA5PTR{IN88US=>	M4Wxc3NCVkeHUh?=
T47D	NYHoSVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnCNIxKSzVyPUOuNVA2PThizszN	M{juTnNCVkeHUh?=
NCI-H2029	M3PCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7ofJdKSzVyPUOuNlI1PzdizszN	NUTJTGdGW0GQR1XS
KARPAS-299	M1vrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XVTmlEPTB;Mz6yOlAzPyEQvF2=	NV\4TlZCW0GQR1XS
KM-H2	NU\SO2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\SXJZ6UUN3ME2zMlMxPjhizszN	M2K0fnNCVkeHUh?=
CHP-134	NIryeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInTdZlKSzVyPUOuOFc{QSEQvF2=	MWjTRW5ITVJ?
22RV1	M2rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf5elNLUUN3ME2zMlQ6OTZ6IN88US=>	Ml7ZV2FPT0WU
NB5	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q4RWlEPTB;Mz61NFY5QSEQvF2=	MmfSV2FPT0WU
CW-2	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu4TWM2OD1\|LkW1N\|E1KM7:TR?=	M1v0S3NCVkeHUh?=
EFO-21	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTNwNU[5OEDPxE1?	NXTEc2RXW0GQR1XS
HuH-7	M{niXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDQTWM2OD1\|LkW4OFE1KM7:TR?=	NX7nU3FuW0GQR1XS
ALL-PO	NFm2c\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TifWlEPTB;Mz62NlM{PSEQvF2=	NWi3UoZnW0GQR1XS
EM-2	NWCz[JBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrjeWRKSzVyPUOuOlkxOTFizszN	MWPTRW5ITVJ?
KLE	M{XHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrxZnBKSzVyPUOuO\|MxOjlizszN	NUfFU3NCW0GQR1XS
NEC8	NGHHfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTNwOUG4NFgh\|ryP	M3fMOXNCVkeHUh?=
KP-N-YN	NYHlb4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTNwOUO0O\|Yh\|ryP	MX;TRW5ITVJ?
SK-MEL-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzQTWM2OD12LkCzOVE5KM7:TR?=	MXPTRW5ITVJ?
CAL-54	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MontTWM2OD12LkC1PVEh\|ryP	MUnTRW5ITVJ?
MS-1	NGLyOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfBb2hkUUN3ME20MlE3OTV3IN88US=>	MmGyV2FPT0WU
NCI-H209	M2fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jKVWlEPTB;ND6yPVk6QSEQvF2=	Mn;iV2FPT0WU
NOMO-1	NUj4SGd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\STWM2OD12LkOyNVMyKM7:TR?=	MV7TRW5ITVJ?
RPMI-2650	NH3ZTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzkTWM2OD12LkO2N\|I4KM7:TR?=	MW\TRW5ITVJ?
NCI-H810	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonSTWM2OD12LkO5O\|M3KM7:TR?=	M4GwS3NCVkeHUh?=
Ca9-22	NGLJO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTRwNEW2PVEh\|ryP	M3XRRXNCVkeHUh?=
ES4	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPDTWM2OD12LkS3NFk2KM7:TR?=	M4TobHNCVkeHUh?=
ES6	NVu0ZVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nVdmlEPTB;ND60PVY2PyEQvF2=	NH;sRohUSU6JRWK=
DMS-114	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTRwNUS2PVEh\|ryP	NVjxNnY2W0GQR1XS
ONS-76	M1;OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUToRXZ7UUN3ME20MlU4QTVizszN	MXPTRW5ITVJ?
K-562	NH3jeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTRwN{O4NVQh\|ryP	MYDTRW5ITVJ?
MHH-NB-11	M2jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTRwN{W0OlEh\|ryP	NEXWUWpUSU6JRWK=
Calu-3	NHnP[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDYU5JKSzVyPUSuO\|g2PDhizszN	MlrnV2FPT0WU
HT55	NU\zZVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nRemlEPTB;ND64OFU1PSEQvF2=	MoDMV2FPT0WU
SK-N-FI	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\LTWM2OD12Lki1NFA6KM7:TR?=	MmnTV2FPT0WU
ES1	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTRwOE[wOVch\|ryP	MX\TRW5ITVJ?
SF126	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17Ue2lEPTB;ND65N\|E5PCEQvF2=	NFyyRXRUSU6JRWK=
ES5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTVwMUK0Nlch\|ryP	MmW0V2FPT0WU
LoVo	M4CxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HpXmlEPTB;NT6xOVg4OSEQvF2=	NYLOcodWW0GQR1XS
SNU-387	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTVwM{KzN\|kh\|ryP	NYjaUJlnW0GQR1XS
C8166	NX7xcoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTVwM{[zN\|kh\|ryP	NV23cWoyW0GQR1XS
LS-1034	NEHER3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHrTnhKSzVyPUWuOFI{ODdizszN	NF3iOolUSU6JRWK=
GR-ST	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jtd2lEPTB;NT61NlIxOSEQvF2=	Ml6zV2FPT0WU
NCI-H1092	NEDaUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17COGlEPTB;NT63Nlg1OyEQvF2=	M3;MSHNCVkeHUh?=
647-V	NXuz[5FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXH2OmI3UUN3ME21Mlc1PzB4IN88US=>	NGH4eYZUSU6JRWK=
EW-13	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLTTWM2OD13Lke2OlI4KM7:TR?=	MlPSV2FPT0WU
KGN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjQRmxKSzVyPU[uNFk6OjFizszN	NIjnNnZUSU6JRWK=
D-423MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPhTWM2OD14LkSwNlg1KM7:TR?=	NELl[YRUSU6JRWK=
ECC10	M{XDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLTTWM2OD15LkGwNVAyKM7:TR?=	NHTMbotUSU6JRWK=
TE-5	M3HtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH71boNKSzVyPUeuOFEzQThizszN	NXzBUo1SW0GQR1XS
P12-ICHIKAWA	NH7sfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3zXpNKSzVyPUeuOFU2OjNizszN	MX3TRW5ITVJ?
NCI-H82	NFK3XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nGcWlEPTB;Nz60OVcxOSEQvF2=	MV\TRW5ITVJ?
NCI-H1993	M{n2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PoWmlEPTB;Nz64N\|A3OyEQvF2=	M37UWXNCVkeHUh?=
RH-1	NHrJV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HEOmlEPTB;Nz64OVI1PCEQvF2=	NUjJb\|U3W0GQR1XS
SW948	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;R[IljUUN3ME23Mlk3ODR7IN88US=>	MVjTRW5ITVJ?
CAL-33	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XrN2lEPTB;Nz65PVk{QCEQvF2=	NWT1cJdPW0GQR1XS
U-266	M4ew[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRThwMUW3O\|ch\|ryP	M{XIVXNCVkeHUh?=
CAL-72	M4S1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRThwMkCzNkDPxE1?	NF6wVYtUSU6JRWK=
SNU-423	M4TM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjvTWM2OD17LkO2OlY3KM7:TR?=	NHrScJZUSU6JRWK=
KG-1	M1;6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[yZ3BnUUN3ME25MlU5PDV4IN88US=>	NI\1cldUSU6JRWK=
HCC1395	M1zDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPhTnh[UUN3ME25MlkzOzV{IN88US=>	MmTwV2FPT0WU
BE-13	M1;6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTzTWM2OD1zMD64PFkzKM7:TR?=	MUfTRW5ITVJ?
MKN7	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vlSmlEPTB;MUCuPVc3PSEQvF2=	NEHlNIdUSU6JRWK=
697	NW\RWpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPve\|lKSzVyPUGxMlE1PzJizszN	NHzCcG5USU6JRWK=
LU-135	NHLE[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTFzLkKzNFch\|ryP	M3LqSnNCVkeHUh?=
ES7	M2DpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm5UGRKSzVyPUGxMlM{OTNizszN	MlvVV2FPT0WU
SK-HEP-1	NFjPfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFzLke2OFYh\|ryP	NG\aPIlUSU6JRWK=
BEN	M4nBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnmSYVlUUN3ME2xNU45PTFizszN	MoHqV2FPT0WU
NCI-H1770	NXjVcHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrXeGlKSzVyPUGyMlEzPiEQvF2=	M{\Nb3NCVkeHUh?=
SW13	NVL5RmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTF{LkG1OFEh\|ryP	NFe0TXFUSU6JRWK=
MZ1-PC	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moe0TWM2OD1zMj61OFUzKM7:TR?=	MkHRV2FPT0WU
Mo-T	M1TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLHTWM2OD1zMj63OFIyKM7:TR?=	M{jtN3NCVkeHUh?=
HLE	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTF{LkiyNVUh\|ryP	NH74TIFUSU6JRWK=
RCC10RGB	M2rBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnzbI0{UUN3ME2xN{43PzFizszN	MlPzV2FPT0WU
COLO-320-HSR	M2nUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LZ[GlEPTB;MUOuO\|M5OSEQvF2=	M2H0O3NCVkeHUh?=
BHT-101	NF3GWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV31U\|hEUUN3ME2xN{45OzR3IN88US=>	M2TP[nNCVkeHUh?=
OCUB-M	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fSeWlEPTB;MUSuNVYxOiEQvF2=	NUfwTY9bW0GQR1XS
MEG-01	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUOzZZNiUUN3ME2xOE4{PzB6IN88US=>	MX;TRW5ITVJ?
RS4-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXQdJZNUUN3ME2xOE44PDJizszN	MUDTRW5ITVJ?
MN-60	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[xTWM2OD1zND63PFk1KM7:TR?=	NHTKW\|lUSU6JRWK=
NCI-H1304	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XwfWlEPTB;MUWuNFQzPSEQvF2=	MWXTRW5ITVJ?
Ramos-2G6-4C10	NWPMcZUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rXcmlEPTB;MUWuNFU5OSEQvF2=	Mo\PV2FPT0WU
NCI-H2342	NEHqVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDvTWM2OD1zNT6yNFQ1KM7:TR?=	M3LUOnNCVkeHUh?=
LAN-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXoOJJKSzVyPUG1MlQ1OTRizszN	Ml;1V2FPT0WU
JVM-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTF3LkW3OFgh\|ryP	NFvJXXpUSU6JRWK=
P30-OHK	NF:wTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjNdWZKSzVyPUG2MlA3OTRizszN	M1PHeHNCVkeHUh?=
C-33-A	M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPpTWM2OD1zNj62NlE1KM7:TR?=	NUG0XI46W0GQR1XS
RPMI-8866	NELsUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LFb2lEPTB;MU[uPFQ6PiEQvF2=	MnW3V2FPT0WU
NCI-H630	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTF4Lki1N\|ch\|ryP	MVTTRW5ITVJ?
KYSE-140	NHHnPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PZW2lEPTB;MUeuNlAzQCEQvF2=	NV\DUWhwW0GQR1XS
T84	NHL2bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHTTWM2OD1zOD64Olk2KM7:TR?=	NV7keI9yW0GQR1XS
KU-19-19	NXvCSnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULjTllmUUN3ME2xPE46PjB6IN88US=>	MXjTRW5ITVJ?
BALL-1	M2HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PDPGlEPTB;MUmuN\|M6QSEQvF2=	M4rpfXNCVkeHUh?=
Calu-6	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rme2lEPTB;MUmuOFkzKM7:TR?=	M3exfXNCVkeHUh?=
EGI-1	NXHNTZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PoPWlEPTB;MUmuOVk5KM7:TR?=	M1HQdXNCVkeHUh?=
MFH-ino	NEXZOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fyOGlEPTB;MUmuO\|Q2PCEQvF2=	MkLqV2FPT0WU
GB-1	NWLwWIROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTJyLkO1N\|Uh\|ryP	NEHKfHBUSU6JRWK=
NCI-H1693	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTJPGxKSzVyPUKwMlY2ODVizszN	M1fUSXNCVkeHUh?=
SW1116	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS2UZJCUUN3ME2yNE46OzZ{IN88US=>	NE\WPI1USU6JRWK=
H-EMC-SS	NXOyUI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLtTWM2OD1{Mj6wOFUh\|ryP	M3rTWXNCVkeHUh?=
D-502MG	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHoXIdNUUN3ME2yNk45OjZzIN88US=>	MljnV2FPT0WU
IA-LM	M1jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJ\|LkK0PVMh\|ryP	MoexV2FPT0WU
SW1463	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTJ\|Lke5JO69VQ>?	MnnPV2FPT0WU
JAR	NXfZNmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LnTWlEPTB;MkSuN\|I6OyEQvF2=	M2Hac3NCVkeHUh?=
HT	NInxN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPYTGRKSzVyPUK0MlQ4PTNizszN	NF\KW5NUSU6JRWK=
LCLC-103H	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33Bc2lEPTB;MkSuPFQ1QSEQvF2=	NVLxT5prW0GQR1XS
SNU-449	M4\T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJ2Lki3OFEh\|ryP	M{GzZnNCVkeHUh?=
KE-37	NH:yVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS3WnIzUUN3ME2yOU4xQTJ6IN88US=>	MXPTRW5ITVJ?
NCI-H1623	Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjYTWM2OD1{Nz6xN\|A{KM7:TR?=	MlzLV2FPT0WU
MOLT-13	M1;uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7WTWM2OD1{Nz6zOVE3KM7:TR?=	NYHzPGJpW0GQR1XS
COLO-741	M1TjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTNzLkOzN\|Mh\|ryP	M1[z[XNCVkeHUh?=
NB6	NUjQcG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHiTWM2OD1\|Mj6yPFc3KM7:TR?=	NXLlRW56W0GQR1XS
MOLT-16	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnr5TWM2OD1\|Mz6wNFU2KM7:TR?=	NH\aNIJUSU6JRWK=
IST-MES1	NYLXV4dzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfVfpJ7UUN3ME2zOE4xPTRzIN88US=>	NXPoPWk1W0GQR1XS
A4-Fuk	NWLrcWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf0SmlEUUN3ME2zOU4xPjZizszN	M{n6c3NCVkeHUh?=
CAL-85-1	NG[4eXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj6Slh3UUN3ME2zOU4zQDF5IN88US=>	MlTlV2FPT0WU
CCRF-CEM	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL5fnJLUUN3ME2zO{4yPTN4IN88US=>	M2jtR3NCVkeHUh?=
HAL-01	NVPL[411T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jlSmlEPTB;M{iuOFg5QSEQvF2=	MUDTRW5ITVJ?
HEL	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTR\|LkO0NFkh\|ryP	NFLoToZUSU6JRWK=
EW-1	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknLTWM2OD12Mz60O\|Y5KM7:TR?=	NWnIRVhwW0GQR1XS
MDA-MB-231	NVe5U444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TXXWlEPTB;NEWuNVE6QSEQvF2=	MkjJV2FPT0WU
ABC-1	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TTPGlEPTB;NE[uPFU{QCEQvF2=	Ml7YV2FPT0WU
NCI-H446	M4HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTR6LkWwOVgh\|ryP	NF\S[JdUSU6JRWK=
MHH-PREB-1	NFHXfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTR7Lk[wNFch\|ryP	MYrTRW5ITVJ?
DOHH-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nGW2lEPTB;NEmuOlY2PiEQvF2=	NYj4WGczW0GQR1XS
GCT	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTR7Lk[5O\|Yh\|ryP	M4LXZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00354185	Terminated	Adult Nasal Type Extranodal NK/T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	May 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)